Antisense Therapeutics – Price Target Raised from $0.305 to $0.43

Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.
Read More